Previous 10 |
-- Plans to Initiate MARIO-275, a Randomized, Global Phase 2 Study in 1H’19-- Bristol-Myers Squibb Company (NYSE: BMY) and Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced a clinical trial collaboration to evaluate Bristol-Myers Squibb's Opdivo in combinati...
CAMBRIDGE, Mass. , Nov. 1, 2018 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced today that an abstract describing data from the expansion of the MARIO-1 Phase 1b Study of IPI-549 in combination with nivolumab in advanced solid tumors has been selected as a late-b...
CAMBRIDGE, Mass. , Oct. 29, 2018 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Monday, November 5, 2018 , at 4:30 p.m. ET to review its third quarter 2018 financial results and provide an update on the company. A live webcast...
News, Short Squeeze, Breakout and More Instantly...
Infinity Pharmaceuticals Inc. Company Name:
INFI Stock Symbol:
NASDAQ Market:
Infinity Pharmaceuticals Inc. Website:
Vancouver, British Columbia--(Newsfile Corp. - April 15, 2024) - Infinitum Copper Corp. (TSXV: INFI) (OTCQB: INUMF) (" Infinitum " or the " Company ") is pleased to announce that it has received acceptance from the TSX Venture Exchange (the " Exchange ") of the previously announced consolidation ...
VANCOUVER, BC / ACCESSWIRE / April 3, 2024 / Infinitum Copper Corp. (TSXV:INFI, OTCQB:INUMF) (" Infinitum " or the " Company ") is pleased to announce the details of a proposed consolidation of its common shares. On March 21, 2024, in accordance with the constating documents of the Company, the ...
VANCOUVER, BC / ACCESSWIRE / March 6, 2024 / Infinitum Copper Corp. (TSXV:INFI)(OTCQB:INUMF) (" Infinitum " or the " Company "). Further to the Company's news release of March 5, 2024 (the " March 5, 2024 News Release "), this is to advise that the Company has amended the terms of its private pl...